help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by TIBBY, S. M.
Right arrow Articles by MURDOCH, I. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by TIBBY, S. M.
Right arrow Articles by MURDOCH, I. A.

Am. J. Respir. Crit. Care Med., Volume 162, Number 4, October 2000, 1251-1256

Exogenous Surfactant Supplementation in Infants with Respiratory Syncytial Virus Bronchiolitis

SHANE M. TIBBY, MARK HATHERILL, SARAH M. WRIGHT, PETER WILSON, ANTHONY D. POSTLE, and IAN A. MURDOCH

Department of Pediatric Intensive Care, Guy's Hospital, London, United Kingdom; and Child Health, Southampton General Hospital, Southampton, United Kingdom

Infants with respiratory syncytial virus (RSV) bronchiolitis are deficient in surfactant, both in quantity and ability to reduce surface tension. New evidence suggests surfactant has a role in maintaining the patency of conducting airways, which has implications for RSV bronchiolitis. A randomized, controlled pilot study was undertaken to assess the effects of exogenous surfactant supplementation to RSV-positive infants on pulmonary mechanics, indices of gas exchange, and the phospholipid composition of bronchoalveolar lavage fluid (BALF). Nineteen ventilated infants (median corrected age 4 wk) received either two doses of surfactant (Survanta, 100 mg/kg) within 24 and 48 h of mechanical ventilation (n = 9), or air placebo (n = 10). Static lung compliance and resistance of infants in the placebo but not in the surfactant-treated group became progressively worse over the first 30 h following enrollment. Although no significant acute changes in gas exchange parameters were seen following surfactant, infants in the surfactant group showed a more rapid improvement in oxygenation and ventilation indices over the first 60 h of ventilation. Surfactant status was assessed from the concentration ratio in BALF of the disaturated phospholipid species dipalmitoylphosphatidylcholine to that of the monounsaturated species palmitoyloleoylphosphatidylcholine. This ratio correlated with both lung compliance (positively) and resistance (negatively), and over time increased in the treated group and declined in placebo infants. The data from this pilot study suggest that functional surfactant has a role in maintaining small airway patency as well as lung compliance in infants infected with RSV and an outcome study is now warranted.




This article has been cited by other articles:


Home page
 Arch. Dis. Child.Home page
M Yanney and H Vyas
The treatment of bronchiolitis
Arch. Dis. Child., September 1, 2008; 93(9): 793 - 798.
[Abstract] [Full Text] [PDF]

Home page
 EDUCATION AND PRACTICEHome page
M. Meates-Dennis
BRONCHIOLITIS
Arch. Dis. Child. Ed. Pract., December 1, 2005; 90(4): ep81 - ep86.
[Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
E. Barbi, E. Faleschini, and S. Bassanese
Do We Really Need More Trials About the Efficacy of Commonly Used Treatments for Bronchiolitis?
Arch Pediatr Adolesc Med, February 1, 2005; 159(2): 196 - 197.
[Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
V. J. King, W. C. Bordley, and M. Viswanathan
Do We Really Need More Trials About the Efficacy of Commonly Used Treatments for Bronchiolitis?--Reply
Arch Pediatr Adolesc Med, February 1, 2005; 159(2): 197 - 197.
[Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
M. Haroon
Can surfactant cure babies with severe bronchiolitis?
Arch. Dis. Child., September 1, 2003; 88(9): 834 - 835.
[Full Text]

Home page
 Pediatr. Rev.Home page
C. A. McCarthy and C. B. Hall
Respiratory Syncytial Virus: Concerns and Control
Pediatr. Rev., September 1, 2003; 24(9): 301 - 309.
[Full Text] [PDF]

Home page
 J. Virol.Home page
Y. Zhang, M. Jamaluddin, S. Wang, B. Tian, R. P. Garofalo, A. Casola, and A. R. Brasier
Ribavirin Treatment Up-Regulates Antiviral Gene Expression via the Interferon-Stimulated Response Element in Respiratory Syncytial Virus-Infected Epithelial Cells
J. Virol., May 15, 2003; 77(10): 5933 - 5947.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. G. Randolph, K. L. Meert, M. E. O'Neil, J. H. Hanson, P. M. Luckett, J. H. Arnold, R. G. Gedeit, P. N. Cox, J. S. Roberts, S. T. Venkataraman, et al.
The Feasibility of Conducting Clinical Trials in Infants and Children with Acute Respiratory Failure
Am. J. Respir. Crit. Care Med., May 15, 2003; 167(10): 1334 - 1340.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
A. Mander, S. Langton-Hewer, W. Bernhard, J. O. Warner, and A. D. Postle
Altered Phospholipid Composition and Aggregate Structure of Lung Surfactant Is Associated with Impaired Lung Function in Young Children with Respiratory Infections
Am. J. Respir. Cell Mol. Biol., December 1, 2002; 27(6): 714 - 721.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Pediatrics, Surfactant, and Cystic Fibrosis in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1581 - 1594.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society 		  ATS Sleep Tracings Quiz